Skip to main content
    • Aa
    • Aa
  • Access
  • Open access
  • Cited by 16
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Mizrahi, Romina 2016. Social Stress and Psychosis Risk: Common Neurochemical Substrates?. Neuropsychopharmacology, Vol. 41, Issue. 3, p. 666.

    Sacchetti, E Magri, C Minelli, A Valsecchi, P Traversa, M Calza, S Vita, A and Gennarelli, M 2016. The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. The Pharmacogenomics Journal,

    Schennach, Rebecca Möller, Hans-Jürgen Obermeier, Michael Seemüller, Florian Jäger, Markus Schmauss, Max Laux, Gerd Pfeiffer, Herbert Naber, Dieter Schmidt, Lutz G. Gaebel, Wolfgang Klosterkötter, Joachim Heuser, Isabella Maier, Wolfgang Lemke, Matthias R. Rüther, Eckart Klingberg, Stefan Gastpar, Markus Musil, Richard Spellmann, Ilja and Riedel, Michael 2016. Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methods. International Journal of Methods in Psychiatric Research, Vol. 25, Issue. 1, p. 3.

    Watmuff, Bradley Berkovitch, Shaunna S. Huang, Joanne H. Iaconelli, Jonathan Toffel, Steven and Karmacharya, Rakesh 2016. Disease signatures for schizophrenia and bipolar disorder using patient-derived induced pluripotent stem cells. Molecular and Cellular Neuroscience, Vol. 73, p. 96.

    Weinmann, Stefan and Koesters, Markus 2016. Mental health service provision in low and middle-income countries. Current Opinion in Psychiatry, Vol. 29, Issue. 4, p. 270.

    Andreou, Christina Nolte, Guido Leicht, Gregor Polomac, Nenad Hanganu-Opatz, Ileana L. Lambert, Martin Engel, Andreas K. and Mulert, Christoph 2015. Increased Resting-State Gamma-Band Connectivity in First-Episode Schizophrenia. Schizophrenia Bulletin, Vol. 41, Issue. 4, p. 930.

    De Hert, Marc Sermon, Jan Geerts, Paul Vansteelandt, Kristof Peuskens, Joseph and Detraux, Johan 2015. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics. CNS Drugs, Vol. 29, Issue. 8, p. 637.

    Leicht, Gregor Andreou, Christina Polomac, Nenad Lanig, Clarissa Schöttle, Daniel Lambert, Martin and Mulert, Christoph 2015. Reduced auditory evoked gamma band response and cognitive processing deficits in first episode schizophrenia. The World Journal of Biological Psychiatry, Vol. 16, Issue. 6, p. 387.

    Andreou, Christina Faber, Pascal L. Leicht, Gregor Schoettle, Daniel Polomac, Nenad Hanganu-Opatz, Ileana L. Lehmann, Dietrich and Mulert, Christoph 2014. Resting-state connectivity in the prodromal phase of schizophrenia: Insights from EEG microstates. Schizophrenia Research, Vol. 152, Issue. 2-3, p. 513.

    Jäger, Markus Weiser, Prisca Becker, Thomas Frasch, Karel Längle, Gerhard Croissant, Daniela Steinert, Tilman Jaeger, Susanne and Kilian, Reinhold 2014. Identification of psychopathological course trajectories in schizophrenia. Psychiatry Research, Vol. 215, Issue. 2, p. 274.

    Levine, Stephen Z. and Leucht, Stefan 2014. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: Analysis of amisulpride vs placebo in three clinical trials. Schizophrenia Research, Vol. 156, Issue. 1, p. 107.

    Nordon, C. Rouillon, F. Azorin, J. M. Barry, C. Urbach, M. and Falissard, B. 2014. Trajectories of antipsychotic response in drug-naive schizophrenia patients: results from the 6-month ESPASS follow-up study. Acta Psychiatrica Scandinavica, Vol. 129, Issue. 2, p. 116.

    Pelayo-Terán, J. M. Diaz, F. J. Pérez-Iglesias, R. Suárez-Pinilla, P. Tabarés-Seisdedos, R. de León, J. and Crespo-Facorro, B. 2014. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychological Medicine, Vol. 44, Issue. 01, p. 37.

    Chen, Lei Johnston, Joseph A Kinon, Bruce J Stauffer, Virginia Succop, Paul Marques, Tiago R and Ascher-Svanum, Haya 2013. The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry, Vol. 13, Issue. 1,

    Hasey, Gary Marcel and Kiang, Michael 2013. A Review of Recent Literature Employing Electroencephalographic Techniques to Study the Pathophysiology, Phenomenology, and Treatment Response of Schizophrenia. Current Psychiatry Reports, Vol. 15, Issue. 9,

    Tiwari, Arun K. Brandl, Eva J. Weber, Caroline Likhodi, Olga Zai, Clement C. Hahn, Margaret K. Lieberman, Jeffrey A. Meltzer, Herbert Y. Kennedy, James L. and Müller, Daniel J. 2013. Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in Schizophrenia Patients. Journal of Clinical Psychopharmacology, Vol. 33, Issue. 1, p. 11.


The heterogeneity of antipsychotic response in the treatment of schizophrenia

  • M. Case (a1), V. L. Stauffer (a1), H. Ascher-Svanum (a2), R. Conley (a1), S. Kapur (a3), J. M. Kane (a4), S. Kollack-Walker (a1), J. Jacob (a1) and B. J. Kinon (a2)
  • DOI:
  • Published online: 07 October 2010

Schizophrenia is a heterogeneous disorder in terms of patient response to antipsychotic treatment. Understanding the heterogeneity of treatment response may help to guide treatment decisions. This study was undertaken to capture inherent patterns of response to antipsychotic treatment in patients with schizophrenia, characterize the subgroups of patients with similar courses of response, and examine illness characteristics at baseline as possible predictors of response.


Growth mixture modeling (GMM) was applied to data from a randomized, double-blind, 12-week study of 628 patients with schizophrenia or schizo-affective disorder treated with risperidone or olanzapine.


Four distinct response trajectories based on Positive and Negative Syndrome Scale (PANSS) total score over 12 weeks were identified: Class 1 (420 patients, 80.6%) with moderate average baseline PANSS total score showing gradual symptom improvement; Class 2 (65 patients, 12.5%) showing rapid symptom improvement; Class 3 (24 patients, 4.6%) with high average baseline PANSS total score showing gradual symptom improvement; and Class 4 (12 patients, 2.3%) showing unsustained symptom improvement. Latent class membership of early responders (ER) and early non-responders (ENR) was determined based on 20% symptom improvement criteria at 2 weeks and ultimate responders (UR) and ultimate non-responders (UNR) based on 40% symptom improvement criteria at 12 weeks. Baseline factors with potential influence on latent class membership were identified.


This study identified four distinct treatment response patterns with predominant representation of responders or non-responders to treatment in these classes. This heterogeneity may represent discrete endophenotypes of response to treatment with different etiologic underpinnings.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      The heterogeneity of antipsychotic response in the treatment of schizophrenia
      Available formats
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      The heterogeneity of antipsychotic response in the treatment of schizophrenia
      Available formats
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      The heterogeneity of antipsychotic response in the treatment of schizophrenia
      Available formats
The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <>. The written permission of Cambridge University Press must be obtained for commercial re-use.
Corresponding author
*Address for correspondence: J. Jacob, Ph.D., Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA. (Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

O Agid , S Kapur , T Arenovich , RB Zipursky (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry 60, 12281235.

A Aleman , RS Kahn , JP Selten (2003). Sex differences in the risk of schizophrenia: evidence from meta-analysis. Archives of General Psychiatry 60, 565571.

H Ascher-Svanum , AW Nyhius , DE Faris , BJ Kinon , RW Baker , A Shekar (2008). Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophrenia Bulletin 34, 11631171.

JL Ayuso-Gutierrez , JM del Rio Vega (1997). Factors influencing relapse in the long-term course of schizophrenia. Schizophrenia Research 28, 199206.

TR Barnes (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672676.

CU Correll , AK Malhotra , S Kaushik , M McMeniman , JM Kane (2003). Early prediction of antipsychotic response in schizophrenia. American Journal of Psychiatry 160, 20632065.

DL Garver , JA Holcomb , JD Christensen (2000). Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. Journal of Clinical Psychiatry 61, 964972.

ID Glick , CA Bossie , L Alphs , CM Canuso (2009). Onset and persistence of antipsychotic response in patients with schizophrenia. Journal of Clinical Psychopharmacology 29, 542547.

JM Haro , D Novick , D Suarez , S Ochoa , M Roca (2008). Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32, 12871292.

PD Harvey , J Rabinowitz , M Eerdekens , M Davidson (2005). Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. American Journal of Psychiatry 162, 18881895.

DW Heinrichs , TE Hanlon , Jr. WT Carpenter (1984). The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10, 388398.

SR Kay , A Fiszbein , LA Opler (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261276.

RSE Keefe , TE Goldberg , PD Harvey , JM Gold , MP Poe , L Coughenour (2004). The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research 68, 283297.

RW Kerwin , S Osborne (2000). Antipsychotic drugs. Medicine 28, 2325.

BJ Kinon , L Chen , H Ascher-Svanum , VL Stauffer , S Kollack-Walker , JL Sniadecki , JM Kane (2008). Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research 102, 230240.

BJ Kinon , L Chen , H Ascher-Svanum , VL Stauffer , S Kollack-Walker , W Zhou , S Kapur , JM Kane (2010). Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 35, 581590.

L Kleinman , J Lieberman , S Dube , R Mohs , Y Zhao , B Kinon , W Carpenter , PD Harvey , MF Green , RS Keefe , L Frank , L Bowman , DA Revicki (2009). Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophrenia Research 107, 275285.

T Lencz , DG Robinson , K Xu , J Ekholm , S Sevy , H Gunduz-Bruce , MG Woerner , JM Kane , D Goldman , AK Malhotra (2006). DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. American Journal of Psychiatry 163, 529531.

S Leucht , R Busch , W Kissling , JM Kane (2007). Early prediction of antipsychotic nonresponse among patients with schizophrenia. Journal of Clinical Psychiatry 68, 352360.

SZ Levine , J Rabinowitz (2010). Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophrenia Bulletin 36, 624632.

JA Lieberman , TS Stroup , JP McEvoy , MS Swartz , RA Rosenheck , DO Perkins , RS Keefe , SM Davis , CE Davis , BD Lebowitz , J Severe , JK Hsiao ; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 12091223.

I Lipkovich , W Deberdt , JG Csernansky , P Buckley , J Peuskens , S Kollack-Walker , M Rotelli , JP Houston (2009). Defining ‘good’ and ‘poor’ outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Research 170, 161167.

H Liu-Seifert , D Adams , BJ Kinon (2005). Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine 3, 21.

S Miyamoto , GE Duncan , CE Marx , JA Lieberman (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 10, 79–104.

HJ Moller (2005). Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues. World Journal of Biological Psychiatry 6, 247263.

SA Montgomery , M Asberg (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382389.

B Muthén , H Brown (2009). Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Statistics in Medicine 28, 33633385.

D Naber , S Moritz , M Lambert , FG Rajonk , R Holzbach , R Mass , B Andresen (2001). Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 50, 7988.

DO Perkins (2002). Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry 63, 11211128.

DO Perkins (2005). Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. American Journal of Psychiatry 162, 17851804.

J Rabinowitz , PD Harvey , M Eerdekens , M Davidson (2006). Premorbid functioning and treatment response in recent-onset schizophrenia. British Journal of Psychiatry 189, 3135.

P Thieda , S Beard , A Richter , J Kane (2003). An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatric Services 54, 508516.

A Ucok , A Polat , A Genc , S Cakir , N Tarun (2004). Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. Journal of Psychiatric Research 38, 163168.

R Uher , B Muthén , D Souery , O Mors , J Jaracz , A Placentino , A Petrovic , A Zobel , N Henigsberg , M Rietschel , KJ Aitchison , A Farmer , P McGuffin (2010). Trajectories of change in depression severity during treatment with antidepressants. Psychological Medicine 40, 13671377.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Type Description Title
Supplementary Materials

Case supplementary material

 Unknown (221 KB)
221 KB